VEGFA and hepatocellular carcinoma: Hypervascular features hold the cornerstone of anti-angiogenic regimens, primarily as the inhibition of vascular endothelial growth factor and its receptor (VEGF/VEGFR) and fibroblast growth factor and its receptor (FGF/FGFR) pathways in advanced HCC, yielding uniquely high objective response rates (ORRs) [5].